CardiGemini combines 12/64-lead high-density ECG with virtual 3D cardiac modeling to deliver non-invasive ischemia risk assessment in 5 minutes — with 87% accuracy on significant ischemia and full clinical visualization.
Cardiovascular disease claims 17.9 million lives annually — yet over half of cases involve silent early-stage ischemia. Conventional tools leave high-risk patients undiagnosed until catastrophe strikes.
Standard 12-lead ECG sensitivity for early ischemia is only 30–50%, frequently missing diabetic, female, and elderly patients.
Catheter angiography exposes patients to contrast and radiation. Stress tests are unsuitable for frail, diabetic, or post-operative populations.
Existing non-invasive tools cannot pinpoint LAD/LCX/RCA territories, leaving clinicians without visual decision support.
Over half of CAD patients show no symptoms before a major event — symptom-driven care leaves them invisible until it's too late.
CT-FFR, SPECT/PET, and cardiac MRI carry multi-million-dollar capex plus radiation or contrast burden — out of reach for primary care and screening.
PCI / CABG patients lack a repeatable, low-risk non-invasive tool to monitor residual ischemia and restenosis after revascularization.
2–4× higher cardiovascular risk; autonomic neuropathy masks symptoms, fueling silent ischemia.
Post-menopause estrogen loss; CAD symptoms are often misread as anxiety or menopause, delaying diagnosis.
Up to 30% restenosis or residual ischemia within 5 years — needs repeatable non-invasive monitoring.
Doubled CAD risk with first-degree premature CAD; screen 10 years earlier than the youngest affected relative.
CVD is the #1 cause of death in CKD; renal function limits CT/contrast imaging, leaving few options.
75% of CVD deaths occur in this group; low tolerance for radiation, contrast, and stress testing demands safer alternatives.
Every mainstream tool compromises on sensitivity, invasiveness, cost, or repeatability — none simultaneously delivers early detection, broad accessibility, and frequent follow-up.
| Tool | Sensitivity | Invasive | Radiation / Contrast | Equipment Cost | Repeatable Follow-Up |
|---|---|---|---|---|---|
| Standard 12-Lead ECG | 30–50% | ✓ No | ✓ No | Low | Limited |
| Stress Echo / ECG | Moderate | ✓ No | ✓ No | Moderate | Partial |
| Catheter Angiography | High | ✗ Yes | ✗ Yes | High | ✗ No |
| CT-FFR | High | ✓ No | ✗ Yes (CT) | Very High | ✗ No |
| SPECT / PET | High | ✓ No | ✗ Yes (Radiotracer) | Very High | ✗ No |
| CardiGemini Ischemia Imaging | 78–87% | ✓ No | ✓ None | Moderate | ✓ Yes |
A two-part platform — high-density hardware paired with AI imaging — built to scale from ED triage to post-operative follow-up, from academic medical centers to outpatient screening.
Transforms multi-lead ECG signals into virtual 3D ischemia maps with quantified severity scores and automated PDF reporting.
High-density ECG patch/vest covering anterior, lateral, posterior, and limb leads — capturing local ischemia signatures invisible to standard ECG.
Built on 20+ years of cardiac electrophysiology research at NCU, our patented algorithms reconstruct virtual 3D ischemia maps from ECG signals — with quantitative localization of affected territories.
Deep learning captures subtle ST-T variations and electrophysiological anomalies that elude conventional ECG screening.
No contrast, no radiation, no pharmacological stress — suitable for diabetic, female, elderly, and post-operative populations requiring repeat monitoring.
10–20 min full-heart 3D imaging with instant cloud-AI scoring and auto-generated PDF reports — telemedicine ready.
12-64 lead patch or vest, clinic / bedside ready
10-min high-resolution capture at 1 kHz
Vector field reconstruction + localization
3D map + bull's-eye + risk score PDF
Multi-site clinical validation and independent reader performance — recognized with TFDA Priority Review and NSTC Innovation Program funding.
| Dimension | CardiGemini | Medtronic CardioInsight | CorVista System | Anumana ECG-AI |
|---|---|---|---|---|
| 3D Ischemia Mapping | ✓ | ✓ (需 CT) | ✗ | ✗ |
| Zero Radiation / Contrast | ✓ | ✗ (需 CT) | ✓ | ✓ |
| Outpatient / Screening | ✓ | 電生理實驗室 | ✓ | ✓ |
| Hardware Cost | Moderate | Very High (252-electrode disposable) | Moderate | Low (Software only) |
| Indication Breadth | Acute + Post-op Follow-up | Arrhythmia + Local Ischemia | CAD rule-out | LEF detection |
Whether you're a healthcare provider, an investor, or simply want to learn more — reach us via the form below. We respond within two business days.
Xinying Smart Medical Device Co., Ltd.
(鈊穎智慧醫療器材股份有限公司)
Business hours: Mon–Fri 09:00–18:00 (GMT+8)
